Polen Capital Management LLC Reduces Position in IDEXX Laboratories, Inc. $IDXX

Polen Capital Management LLC cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 960,537 shares of the company’s stock after selling 166,610 shares during the quarter. IDEXX Laboratories comprises approximately 2.8% of Polen Capital Management LLC’s holdings, making the stock its 15th biggest position. Polen Capital Management LLC’s holdings in IDEXX Laboratories were worth $649,832,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the third quarter valued at about $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories during the fourth quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC increased its position in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares during the period. Wormser Freres Gestion increased its position in shares of IDEXX Laboratories by 671.4% during the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 47 shares during the period. Finally, WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the second quarter valued at about $30,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 0.2%

IDXX stock opened at $557.91 on Friday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company’s 50 day moving average is $563.14 and its 200 day moving average is $628.16. The stock has a market cap of $44.01 billion, a price-to-earnings ratio of 41.08, a price-to-earnings-growth ratio of 3.05 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IDXX. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. UBS Group decreased their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Stifel Nicolaus decreased their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.